Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05626712 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
A Phase 1 study of Type 1 Diabetes and Diabetes Mellitus, Type 1, sponsored by Creative Medical Technology Holdings.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05626712: Recruiting Phase 1 study of Type 1 Diabetes and Diabetes Mellitus, Type 1, sponsored by Creative Medical Technology Holdings.
NCT05626712 is a Phase 1 study of Type 1 Diabetes and Diabetes Mellitus, Type 1 that is actively recruiting participants, run by Creative Medical Technology Holdings. The registered enrollment target is 18 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05626712, a Phase 1 study of Type 1 Diabetes and Diabetes Mellitus, Type 1, is actively recruiting participants, sponsored by Creative Medical Technology Holdings.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
Primary Outcome
The primary outcome to be assessed is tolerability and safety of the CELZ-201 therapy. The incidence of adverse events (grade 2 or above as per CTCAE version 5.0) in both groups at 6 months.
Conditions Studied
Interventions
- OTHER Control Group
- BIOLOGICAL CELZ-201 Administration
Study Locations (1)
Florida
- Diabetes Research Institute, University of Miami Miller School of Medicine - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-04-07 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 1 |
What NCT05626712 shows while recruiting
NCT05626712 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Control Group is the first listed.
NCT05626712 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05626712 about?
NCT05626712 is a clinical study titled "Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes". The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
What is the current status of trial NCT05626712?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-04-07. Estimated completion is 2028-01-31.
What conditions does trial NCT05626712 study?
This clinical trial studies the following conditions: Type 1 Diabetes, Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT05626712?
The interventions under investigation include: Control Group (OTHER), CELZ-201 Administration (BIOLOGICAL).
Who is sponsoring clinical trial NCT05626712?
This trial is sponsored by Creative Medical Technology Holdings, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05626712 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05626712's enrollment target sits among peer trials
18 159th of 198 higher than 39 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Denosumab for Type 1 Diabetes
RECRUITING · Phase 1
-
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
RECRUITING · Phase 1
-
Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
RECRUITING · Phase 1
-
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI